secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001104659-23-120428
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01
LLM model:  deepseek-v4-flash:cloud@v2

NRX Pharmaceuticals dismisses KPMG as auditor, appoints Salberg & Company
-------------------------------------------------------------------------

- KPMG dismissed effective Nov 15, 2023; no adverse opinions or disagreements in prior years.
- KPMG reports included a going concern paragraph for years ended Dec 31, 2022 and 2021.
- Material weakness in segregation of duties identified for 2021 and quarters of 2022, remediated by Dec 31, 2022.
- Salberg & Company appointed as independent auditor for fiscal year 2023 effective Nov 17, 2023.
- No prior consultations with Salberg on accounting principles or reportable events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923120428/0001104659-23-120428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923120428/tm2331302d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer